Clinical Indications for Growth Hormone Therapy
Advances in Pediatrics · 2022-08 · 69 (1) · 203-217
DOI: 10.1016/j.yapd.2022.03.005 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Advances in Pediatrics, 2022-08. Verfasst von Melinda Danowitz und 1 weiteren Autor:innen. Beteiligte Einrichtung: CHOP Division of Pediatric Endocrinology, Abramson Building, Office 804F, 3401 Civic Center Boulevard, Philadelphia, PA 19104, USA. Hauptthemen laut MEDLINE: Dwarfism, Human Growth Hormone, Prader-Willi Syndrome, Turner Syndrome. Die Arbeit wurde bisher 68-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NICHD NIH HHS, Pfizer, Eunice Kennedy Shriver National Institute of Child Health and Human Development.
Abstract (Originalsprache)
Growth hormone (GH) is an injectable medication originally used to replace the deficiency of the hormone, but has expanded to treating conditions that may reduce growth and adult height even when the body maintains endogenous GH production. In the United States, there are 8 Food and Drug Administration (FDA)-approved indications for pediatric GH therapy: GH deficiency, Prader-Willi Syndrome, small for gestational age (SGA) without catch-up growth, idiopathic short stature, Turner syndrome, SHOX gene haploinsufficiency, Noonan Syndrome, and chronic renal insufficiency. We characterize the growth patterns and effects of GH treatment in each of these indications. We also review patterns of growth that warrant referral to a pediatric endocrinologist, as well as safety updates. This review is intended to guide practitioners on the initial evaluation and management of patients with short stature, and the indications for GH therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- CHOP Division of Pediatric Endocrinology, Abramson Building, Office 804F, 3401 Civic Center Boulevard, Philadelphia, PA 19104, USA.
- Children's Hospital of Philadelphia, The Hub for Clinical Collaboration, Division of Endocrinology, 7th floor, 3500 Civic Center Boulevard, Philadelphia, PA 19104, USA; Department of Pediatrics, Perelman School of Medic…
Förderung
- NICHD NIH HHS
- Pfizer
- Eunice Kennedy Shriver National Institute of Child Health and Human Development
- National Institutes of Health
Zitieren
APA
Danowitz, M., & Grimberg, A. (2022). Clinical Indications for Growth Hormone Therapy. Advances in Pediatrics, 69(1), 203-217. https://doi.org/10.1016/j.yapd.2022.03.005
Vancouver
Danowitz M, Grimberg A. Clinical Indications for Growth Hormone Therapy. Advances in Pediatrics. 2022;69(1):203-217. doi:10.1016/j.yapd.2022.03.005
BibTeX
@article{Danowitz2022,
author = {Danowitz, Melinda and Grimberg, Adda},
title = {Clinical Indications for Growth Hormone Therapy},
journal = {Advances in Pediatrics},
year = {2022},
volume = {69},
number = {1},
pages = {203--217},
doi = {10.1016/j.yapd.2022.03.005}
}
EUVIMED